- Stocks
- Healthcare
- NASDAQ: CARA

Price (delayed)

$14.55

Market cap

$728.26M

P/E Ratio

44.09

Dividend/share

N/A

EPS

$0.33

Enterprise value

$710.22M

The quick ratio has surged by 183% year-on-year and by 7% since the previous quarter

Cara Therapeutics's EPS has soared by 113% YoY and by 83% from the previous quarter

Cara Therapeutics's equity has increased by 44% YoY but it has decreased by 7% from the previous quarter

CARA's debt is up by 20% year-on-year but it is down by 7% since the previous quarter

CARA's gross profit is down by 4.6% from the previous quarter

The revenue has declined by 4.6% since the previous quarter

What are the main financial stats of CARA

Market
Valuations
Earnings

Shares outstanding

50.05M

Market cap

$728.26M

Enterprise value

$710.22M

Price to earnings (P/E)

44.09

Price to book (P/B)

3.15

Price to sales (P/S)

5.63

EV/EBIT

52.76

EV/EBITDA

48.49

EV/Sales

5.51

Revenue

$128.92M

EBIT

$13.46M

EBITDA

$14.65M

Free cash flow

$8.82M

Per share
Balance sheet
Liquidity

EPS

$0.33

Free cash flow per share

$0.18

Book value per share

$4.62

Revenue per share

$2.58

TBVPS

$5.01

Total assets

$250.23M

Total liabilities

$19.77M

Debt

$4.89M

Equity

$230.46M

Working capital

$171.83M

Debt to equity

0.02

Current ratio

11.4

Quick ratio

10.55

Net debt/EBITDA

-1.23

Margins
Efficiency
Dividend

EBITDA margin

11.4%

Gross margin

100%

Net margin

10.9%

Operating margin

9.2%

Return on assets

6.7%

Return on equity

7.5%

Return on invested capital

9.1%

Return on capital employed

5.8%

Return on sales

10.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Cara Therapeutics stock price performed over time

Intraday

-0.68%

1 week

4.23%

1 month

8.99%

1 year

-10.13%

YTD

-3.83%

QTD

-32.98%

How have Cara Therapeutics's revenue and profit performed over time

Revenue

$128.92M

Gross profit

$128.92M

Operating income

$11.83M

Net income

$14.03M

Gross margin

100%

Net margin

10.9%

Cara Therapeutics's operating margin has soared by 130% from the previous quarter and by 102% YoY

Cara Therapeutics's operating income has soared by 120% from the previous quarter and by 110% YoY

CARA's net income has soared by 112% YoY and by 67% QoQ

CARA's net margin has surged by 102% year-on-year and by 76% since the previous quarter

What is Cara Therapeutics's growth rate over time

What is Cara Therapeutics stock price valuation

P/E

44.09

P/B

3.15

P/S

5.63

EV/EBIT

52.76

EV/EBITDA

48.49

EV/Sales

5.51

Cara Therapeutics's EPS has soared by 113% YoY and by 83% from the previous quarter

Cara Therapeutics's equity has increased by 44% YoY but it has decreased by 7% from the previous quarter

The P/B is 43% lower than the 5-year quarterly average of 5.5 and 30% lower than the last 4 quarters average of 4.5

CARA's P/S is 99% below its 5-year quarterly average of 433.4 and 67% below its last 4 quarters average of 17.2

The revenue has declined by 4.6% since the previous quarter

How efficient is Cara Therapeutics business performance

CARA's ROA has soared by 112% YoY and by 56% QoQ

CARA's return on invested capital has surged by 112% year-on-year and by 54% since the previous quarter

Cara Therapeutics's return on equity has surged by 111% YoY and by 50% QoQ

Cara Therapeutics's ROS has soared by 102% YoY and by 82% from the previous quarter

What is CARA's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CARA.

How did Cara Therapeutics financials performed over time

The quick ratio has surged by 183% year-on-year and by 7% since the previous quarter

Cara Therapeutics's current ratio has soared by 180% YoY and by 8% from the previous quarter

CARA's debt is 98% smaller than its equity

Cara Therapeutics's equity has increased by 44% YoY but it has decreased by 7% from the previous quarter

The company's debt to equity fell by 33% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.